Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer J. 2016 Nov-Dec;22(6):418–422. doi: 10.1097/PPO.0000000000000228

Figure 1.

Figure 1

Driver mutation profile of lung adenocarcinomas. Generated using data from cbio-portal based on 5 studies of lung adenocarcinoma(65). Targeted small molecule inhibitors are either approved or in development for all of the above mutations (66). “Other” category includes NRAS, FGFR1, and AKT1 which represent <1% of driver mutations.